Who are APD356's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CBD, MediCabilis CBD Oil, Cannabis Extract Oil SR Capsule, Cannabis Sativa Oil, Cesamet™ (nabilone), Cannabis oil.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/apd356.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

APD356 — Competitive Intelligence Brief

APD356 (APD356) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CB2 receptor agonist. Area: Neurology.

phase 2 CB2 receptor agonist CB2 Neurology Small molecule Live · refreshed every 30 min

Target snapshot

APD356 (APD356) — Eisai Inc.. APD356 is a selective agonist of the cannabinoid receptor type 2 (CB2).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
APD356 TARGET	APD356	Eisai Inc.	phase 2	CB2 receptor agonist	CB2
CBD	CBD	Stero Biotechs Ltd.	marketed	Cannabinoid	5-HT1A, TRPV1, GPR55, CB1 (allosteric), CB2 (allosteric)
MediCabilis CBD Oil	MediCabilis CBD Oil	Gold Coast Hospital and Health Service	marketed	Cannabinoid	CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multiple targets)
Cannabis Extract Oil SR Capsule	Cannabis Extract Oil SR Capsule	University of Sao Paulo General Hospital	marketed	Cannabinoid receptor modulator	CB1 receptor, CB2 receptor
Cannabis Sativa Oil	Cannabis Sativa Oil	Fondation pour l'accueil et l'hébérement des personnes âgées	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor
Cesamet™ (nabilone)	Cesamet™ (nabilone)	NEMA Research, Inc.	marketed	Synthetic cannabinoid	CB1 and CB2 cannabinoid receptors
Cannabis oil	Cannabis oil	Assaf-Harofeh Medical Center	marketed	Phytocannabinoid preparation	CB1 receptor, CB2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CB2 receptor agonist class)

Creabilis SA · 1 drug in this class
Eisai Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). APD356 — Competitive Intelligence Brief. https://druglandscape.com/ci/apd356. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab